TIME FOR CHANGEIt's up to you to make a difference

Catheter-associated urinary tract infections (CAUTIs) cause immense problems for the UK National Health Service (NHS)

• Catheters are associated with 80% of all nosocomial UTIs1

• CAUTIs are the largest source of antibiotic-resistant pathogens 2

• 1–4% of patients with CAUTI develop secondary bacteraemia3

• 13–30% of these patients die3

Urinary tract infections (UTIs) are a major source of healthcare

associated infections (HCAIs)

• The bacterial spectrum of nosocomial UTIs is broad and antibiotic resistance is common4

• CAUTIs cause between 21 to 45% of HAIs1

• Hospital-acquired UTIs cost the NHS £124 million every year5

• Every UTI costs an extra £1,327 per patient and blocks a bed for an extra six days5

Urinary tract infections (UTIs) make up a large proportion of healthcare-associated

infections (HCAIs) in the UK – and four out of every five can be traced to

indwelling catheters. (Health Protection Agency, 2009)

This means there is massive scope for both improving the quality of patients’ lives

and saving precious healthcare resources by reducing the occurrence of UTIs.

As a result,

Department of Health

guidelines now make the

reduction of CAUTIs

a priority6

TIME TO CHANGETIME TO CHANGE

UTIs CAN BE REDUCED WITH CORRECT CARE & EVIDENCE BASED TECHNOLOGY

Researcher Study Size Results

Liedberg, Lundeberg & Ekman, 19909 90 patients 80% reduction in CAUTIs

Rupp et al., 200410 >500,000 patient days 57% reduction in CAUTIs

Verleyen et al., 199911 180 patients Bacteriuria reduced by 47%

Newton, Still & Law, 200212 1,757 patients CAUTI/1000 patient days fell from 7.2 to 4.4

Karchmer et al., 200013 27,828 patients Risk of CAUTI reduced by 32%

Bologna et al., 199914 5 ITUs, 108 beds CAUTI/1000 patient days fell from 8.1 to 4.9

Gentry & Cope 200515 133 patients 33.5% reduction in CAUTIs

Seymour 200616 117 patients Risk of CAUTI reduced by 71.2%

Hydrogel

Inflammatory impact on cells of urethral mucosa over 72 hours as

measured on a 4-point scale8†

Bardex® I.C. Foley Catheters are proven more effective than conventional catheters in reducing CAUTIsA wide range of clinical studies clearly show the advantages of Bardex® I.C. Foley Catheters over conventional catheters.

DAMAGED URETHRA

CATHETER

BIOFILM

• Urethra is damaged by friction, the passage of fluids and the inflammatory response to bacteria7

• Catheter surfaces attract bacteria which develop into a biofilm7 which means infection is harder to treat

• This may cause increased pain and discomfort for your patients

Bardex® I.C. anti-infective Foley Catheters work HOW CAUTIs CAUSE DAMAGE

†4-point scale: 1. No oedema or other inflammatory sign 2. Mild oedema and loss of surface epithelium 3. Inflammatory infiltrate and epithelial loss 4. Inflammatory infiltrate, epithelial loss, exudate and haemorrhage.

0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

UTIs CAN BE REDUCED WITH CORRECT CARE & EVIDENCE BASED TECHNOLOGY

Bardex® I.C. Bacti-Guard®* Silver Alloy Uncoated

Latex

“ The results suggest that the use of silver alloy indwelling catheters for catheterising hospitalised adults short-term reduces the risk of catheter acquired urinary tract infection.” 20

Bardex® I.C. Foley Catheters fighting infection and restoring patient comfort

• Unique combination of noble metals and hydrogel coating allows extended slow release of silver ions 21

• These silver ions inhibit biofilm formation and reduce the risk of infection by 32%13

• The occurrence of UTI is 3.7 times greater in patients catheterised with a standard catheter than in patients catheterised with the Bardex® I.C. Foley Catheter with Bacti-Guard®* Silver Alloy coating and Bard® Hydrogel 17

• The Cochrane Review found a 40% reduction in symptomatic infection with silver alloy-coated catheters versus standard catheters18

• The Bardex® I.C. Foley Catheter was the first device to receive a level one recommendation from the Rapid Review Panel to tackle HAIs 19

Isn’t it time to change? REDUCTION OF CAUTIs IS NOW A PRIORITY FOR THE NHS 6

Silver alloy catheters• Preserve the integrity of the urethral mucosa, preventing inflammation, loss of epithelium and formation of biofilm8,22

• Are proven effective in reducing infection compared with conventional catheters10,11

• Biocompatible surface may reduce patient discomfort and aid speedy recovery

Ag+

HYDROGEL

GOLD & PALLADIUM

SILVER

Ag +

Ag +

Bard® Bardex® I.C. Catheter Comprehensive Care Foley TraysRELEASING TIME TO CARE FOR PATIENTS

‘All in One’ anti-infective Foley catheterisation kit

All in One place, Only One price

The best just got

better 19

• Instant protection - for the clinician and the patient

• Everything you need - more time with the patient

• Available in Hospital and on the Drug Tariff

• Less waste

• Encourages best practice

• Cost effective15

• Provides a sterile environment

• Reduces risk of infection - clinically proven anti-infection technology, a true closed system23

Isn't it time you changed?

Image shows

Hospital Foley

Tray with 2 litre

Bed Bag

NURSE ADVICE LINE FREEPHONE 0808 168 4048

For further information on the product range please call 01293 606 786

References: 1.Plowman R, et al. An economic model to assess the cost and benefits of the routine use of silver alloy coated urinary catheters to reduce the risk of urinary tract infections in catheterized patients. Journal of Hospital Infection (2001) 48: 33-42. 2. Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis 2001;7(2):342-347. 3. Pratt RJ, Pellowe C, Loveday HP et al. The epic project: developing national evidence-based guidelines for preventing healthcare associated infections. Phase I: Guidelines for preventing hospital-acquired infections. Department of Health (England). J Hosp Infect 2001;47 Suppl:S3-82. 4. Wagenlehner FM, Weidner W, Naber KG. Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamic considerations. J Hosp Infect 2005;60(3):191-200. 5. Plowman R, et al. The Socioeconomic Burden of Hospital Acquired Infection. Central Public Health Laboratory and London School of Hygiene and Tropical Medicine. London, 1999. 6. www.dh.gov.uk/en/Healthcare/Qualityandproductivity/QIPPworkstreams/DH_115447 7. Trautner BW, Darouiche RO. Role of biofilm in catheter-associated urinary tract infection. Am J Infect Control 2004 May;32(3):177-183. 8. Liedberg H. Catheter induced urethral inflammatory reaction and urinary tract infection. An experimental and clinical study. Scand J Urol Nephrol Suppl 1989;124:1-43. 9. Liedberg H, Lundeberg T, Ekman P. Refinements in the coating of urethral catheters reduces the incidence of catheter-associated bacteriuria. An experimental and clinical study. Eur Urol 1990;17(3):236-240. 10. Rupp ME, Fitzgerald T, Marion N et al. Effect of silver-coated urinary catheters: efficacy, cost-effectiveness, and antimicrobial resistance. Am J Infect Control 2004;32(8):445-450. 11. Verleyen P, De Ridder D, Van Poppel H et al. Clinical application of the Bardex IC Foley catheter. Eur Urol 1999;36(3):240-246. 12. Newton T, Still JM, Law E. A comparison of the effect of early insertion of standard latex and silver-impregnated latex foley catheters on urinary tract infections in burn patients. Infect Control Hosp Epidemiol 2002;23(4):217-218. 13. Karchmer TB, Giannetta ET, Muto CA et al. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. Arch Intern Med 2000;160(21):3294-3298. 14. Bologna RA, Tu LM, Polansky M et al. Hydrogel/silver ion-coated urinary catheter reduces nosocomial urinary tract infection rates in intensive care unit patients: a multicenter study. Urology 1999;54(6):982-987. 15. Gentry H, Cope S (2005) Using silver to reduce catheter-associated urinary tract infections. Nursing Standard. 19, 50, 51-54. Date of acceptance: June 20 2005. 16. Coral Seymour (2006). Audit of catheter-associated UTI using silver alloy-coated Foley Catheters. British Journal of Nursing, 2006, Vol 15, No 11. Date of acceptance: April 2006. 17. Bard data on file. 18. Brosnahan J, Jull A, Tracy C. Types of urethral catheters for management of short-term voidi ng problems in hospitalised adults. Cochrane Database Syst Rev 2004(1):CD004013. 19. Health Protection Agency. Rapid Review Panel Reports: Bardex IC - silver alloy coated hydrogel catheters. Available at http://www.hpa.org.uk/infections/topics_az/rapid_review/pdf/bardex2.pdf. 2004. 20. Schumm K, Lam TBL (2008). Types of urethral catheters for management of short-term voiding problems in hospitalised adults (Review) This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 3 21. BARD. Data on file. 22. Ahearn DG, Grace DT, Jennings MJ et al. Effects of hydrogel/silver coatings on in vitro adhesion to catheters of bacteria associated with urinary tract infections. Curr Microbiol 2000;41(2):120-125. 23. Madeo M, Roodhouse AJ, (2009) Reducing the risks associated with urinary catheters. Nursing Standard. 23, 47-55. 24. Pellowe C, Pratt R, Loveday H et al. The epic project: updating the evidence base for national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. A report with recommendations. Br J Infect Control 2004;59(4):5,6,10-16. 21. ‘Clinical Data’ Compendium, Bard Limited. References: 25. Bard data on file.

It’s up to you to make a difference - 80% of all nosocomial UTIs are CAUTIs1

You can make a difference • Switching from standard catheters to silver alloy-coated catheters significantly reduces the risk of CAUTIs 8,18

• Using the Bard® Comprehensive Care Foley Tray ensures all the items you need are together in one convenient pack

Adopting silver alloy catheters is a proven solution • Bardex® I.C. Foley Catheters with Bacti-Guard®* silver alloy coating and Bard

® Hydrogel have a level one recommendation from the UK Department of Health19 and are recognised by the epic guidelines 24

The efficacy of Bardex® I.C. Foley Catheters is supported by a wealth of clinical evidence • More than 30 studies have shown a reduction in incidence of CAUTIs with Bardex

® I.C. Foley Catheters 25

Ordering Information

Bard Limited, Forest House, Tilgate Forest Business Park, Brighton Road, Crawley, West Sussex RH11 9BP, UKTelephone: 01293 527 888 Fax: 01293 552 428 Bard Customer Care: 01293 529 555

Please consult product labels and inserts for any indication, contraindications, hazards, warnings, cautions and directions for use. Aquafil, Bard, Bardex, Script-easy and Uriplan are trademarks and/or registered trademarks of C.R. Bard, Inc. *Bacti-Guard® is a registered trademark of Bactiguard AB. The Foley Catheters included in the Bardex I.C. System contain Bacti-Guard® silver alloy coating, which is licensed from Bactiguard AB. © 2015 C. R. BARD, Inc. All Rights Reserved 0115/2732

Bardex® I.C. Foley Catheters

** Available through NHS Supply Chain and licensed for use up to 28 days

Bardex® I.C. Foley Tray - Community

Bardex® I.C. Foley Tray - Hospital

Image shows

Hospital Foley

Tray with 2 litre

Bed Bag

Collection System Product Code(Standard Length)

PIP Code Product Code(Female Length)

PIP Code

Bardex® I.C. Foley Catheter with Bacti-Guard®* Silver Alloy Coating and Bard® Hydrogel

Preconnected to Uriplan® Leg Bag D5S direct inlet

D23655S12D23655S14D23655S16

356-7997356-8003356-8029

D23695S12D23695S14D23695S16

356-8094356-8102356-8110

Preconnected to Uriplan® Leg Bag D5M 10cm inlet

D23655M12D23655M14D23655M16

356-7955356-7963356-7971

D23695M12D23695M14D23695M16

356-8060356-8078356-8086

Preconnected to Uriplan® Leg Bag D5L 30cm inlet

D23655L12D23655L14D23655L16

356-7922356-7930356-7948

D23695L12D23695L14D23695L16

356-8037356-8045356-8052

Collection System Product Code(Standard Length)

NHS SC Code** Product Code(Female Length)

NHS SC Code**

Bardex® I.C. Foley Catheter with Bacti-Guard®* Silver Alloy Coating and Bard® Hydrogel

Preconnected to Urinemeter TR2365UM12 TR2365UM14TR2365UM16

FSS798FSS799FSS800

TR2369UM12 TR2369UM14TR2369UM16

FSS807FSS808FSS809

Preconnected to 2 Litre Bed Bag TR23652L12TR23652L14TR23652L16

FSS801FSS802FSS803

TR23692L12TR23692L14TR23692L16

FSS810FSS811FSS813

Preconnected to 500mL Leg Bag TR23655M12TR23655M14TR23655M16

FSS804FSS805FSS806

TR23695M12TR23695M14TR23695M16

FSS814FSS815FSS816

Product Code (Standard Length)

NHS SC Code**

Product Code(Female Length)

NHS SC Code**

Product Code (Standard Length)

PIP Code Product Code(Female Length)

PIP Code

Bardex® I.C. aqUafil® with Bacti-Guard®* Silver Alloy Coating and Bard® Hydrogel Foley Catheters with 10mL prefilled syringe of sterile water

236512UKS FSS370 236912UKS FSS457 D236512S 319-0758 D236912S 319-5062236514UKS FSS372 236914UKS FSS458 D236514S 319-0766 D236914S 319-5070236516UKS FSS374 236916UKS FSS459 D236516S 319-0774 D236916S 319-5088236518UKS FSS375 D236518S 319-0782236520UKS FSS377 D236520S 319-0790236522UKS FSS378 D236522S 319-0808236524UKS FSS381

Freephone: 0800 0121 699 Fax: 01903 875 085

Email: ukcustomercare@crbard.com Web: www.scripteasy.co.uk